Hamlin Capital Management LLC Acquires Shares of 1,355,431 Sanofi (SNY)
Hamlin Capital Management LLC acquired a new position in Sanofi (NYSE:SNY) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,355,431 shares of the company’s stock, valued at approximately $56,725,000. Sanofi accounts for about 2.7% of Hamlin Capital Management LLC’s investment portfolio, making the stock its 22nd largest position. Hamlin Capital Management LLC owned approximately 0.05% of Sanofi as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also modified their holdings of the company. JFS Wealth Advisors LLC boosted its position in shares of Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock worth $166,000 after buying an additional 134 shares during the period. BlackRock Institutional Trust Company N.A. acquired a new position in shares of Sanofi during the first quarter worth $175,000. Rehmann Capital Advisory Group boosted its position in shares of Sanofi by 0.5% in the second quarter. Rehmann Capital Advisory Group now owns 5,571 shares of the company’s stock worth $233,000 after buying an additional 26 shares during the period. Flow Traders U.S. LLC boosted its position in shares of Sanofi by 1.3% in the first quarter. Flow Traders U.S. LLC now owns 6,128 shares of the company’s stock worth $246,000 after buying an additional 81 shares during the period. Finally, Trust Co acquired a new position in shares of Sanofi during the first quarter worth $247,000. 9.42% of the stock is owned by institutional investors and hedge funds.
Shares of Sanofi (NYSE:SNY) traded up 1.36% during trading on Wednesday, hitting $38.67. 4,945,009 shares of the company’s stock were exchanged. Sanofi has a 1-year low of $37.41 and a 1-year high of $51.88. The stock’s 50 day moving average is $39.17 and its 200 day moving average is $40.57. The firm has a market capitalization of $99.54 billion, a PE ratio of 21.57 and a beta of 1.01.
A number of research analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Monday, June 6th. Jefferies Group restated a “hold” rating on shares of Sanofi in a research report on Wednesday, September 14th. Citigroup Inc. restated a “neutral” rating on shares of Sanofi in a research report on Tuesday, June 28th. TheStreet upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Wednesday, July 27th. Finally, Piper Jaffray Cos. initiated coverage on shares of Sanofi in a research report on Friday, September 23rd. They set a “neutral” rating on the stock. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $60.50.
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.